Zevra Therapeutics (ZVRA) Payables (2014 - 2026)

Zevra Therapeutics' Payables history runs 13 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• Quarterly Payables fell 34.41% year-over-year to $11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (down 34.41% YoY) and the FY2025 annual result came in at $11.6 million, down 54.44% from the prior year.
• Payables was $11.7 million for Q1 2026 at Zevra Therapeutics, up from $11.6 million in the prior quarter.
• Across five years, Payables topped out at $28.4 million in Q4 2023 and bottomed at $393000.0 in Q1 2023.
• A 5-year average of $14.0 million and a median of $12.4 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables plunged 84.78% — and 2024, when it soared 5697.71%.
• Zevra Therapeutics' Payables stood at $3.6 million in 2022, then jumped by 686.57% to $28.4 million in 2023, then dropped by 10.38% to $25.5 million in 2024, then plunged by 54.44% to $11.6 million in 2025, then increased by 0.78% to $11.7 million in 2026.
• Business Quant data shows ZVRA's Payables at $11.7 million in Q1 2026, $11.6 million in Q4 2025, and $11.1 million in Q3 2025.